\
&
Contact us
\
&
Contact us
The aim of the Societal Challenge 'Europe in a changing world – Inclusive, innovative and reflective societies' (SC6) is to foster a greater understanding of Europe, provide solutions, and support inclusive, innovative and reflective European societies in a context of unprecedented transformations and growing global interdependencies.
Pressure from increased migration flows, socio-economic and cultural transformations from new forms of human-technology interaction under the fourth industrial revolution, and new developments in European, national and global governance have the potential to significantly impact Europe's future at many levels. At the same time, and linked to these developments, the citizens' trust in many public institutions and their capacities to address effectively these challenges is weakening while their concerns are increasing.
To tackle these challenges, the work programme 2018-2020 will focus on three major themes:
- Migration
- Socio-economic and cultural transformations stemming from the fourth industrial revolution
- Governance for the future
manhei.to@fwo.be
+32 2 550 15 55
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
